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ABSTRACT 
Early onset schizophrenia (EOS) begins in childhood or adolescence. EOS is associated with 
poor treatment response and may benefit from timely use of clozapine. This study aimed to 
identify the predictors of clozapine use in EOS and characterize the clinical profile and 
outcome of clozapine-treated youths with schizophrenia. We conducted a nationwide 
population-based study using linked data from Danish medical registries. We examined all 
incident cases of EOS (i.e., cases diagnosed prior to their 18th birthday) between December 
31st 1994 and December 31st 2006 and characterized their demographic, clinical and 
treatment profiles. We then used multivariable Cox proportional hazard models to identify 
predictors of clozapine treatment in this patient population. We identified 662 EOS cases 
(1.9% of all schizophrenia cases), of whom 108 (17.6%) had commenced clozapine by 
December 31st 2008. Patients had on average 3 antipsychotic trials prior to clozapine 
initiation. The mean interval between first antipsychotic treatment and clozapine initiation 
was 3.2 (2.9) years. Older age at diagnosis of schizophrenia [HR=1.2, 95% CI (1.05-1.4), 
p=0.01]), family history of schizophrenia [HR=2.1, 95%CI (1.1-3.04), p=0.02] and attempted 
suicide [HR=1.8, 95%CI (1.1-3.04), p=0.02] emerged as significant predictors of clozapine 
use. The majority of patients (n=96, 88.8%) prescribed clozapine appeared to have a 
favourable clinical response as indicated by continued prescription redemption and 
benefited in terms of improved occupational outcomes. Our findings support current 
recommendations for the timely use of clozapine in EOS. 
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INTRODUCTION 
A significant proportion of individuals with schizophrenia present during childhood 
or adolescence. Childhood onset schizophrenia (COS), defined as schizophrenia diagnosed 
before the age of 13 years, is rare and affects about 1:40,000 children (Gochman et al. 
2011).  Adolescent onset schizophrenia (AOS) is more common as approximately 5% of 
cases present between the ages of 13-17 years (Cannon et al. 1999). The term early-onset 
schizophrenia (EOS) is commonly used when referring to both COS and AOS.  
EOS is diagnosed using the same criteria as adult onset schizophrenia and lies on the 
same neurobiological continuum (Rapoport et al. 2005). Compared to the adult onset cases, 
EOS is associated with more pronounced developmental and premorbid deviance (Vourdas 
et al. 2003) and greater genetic loading evidenced by higher prevalence of family history of 
psychosis (Ahn et al. 2014), increased rates of genetic abnormalities, particularly copy 
number variations (Addington and  Rapoport, 2009), and possibly more penetrant effects 
for common risk-conferring polymorphisms (Addington and  Rapoport, 2009).  Substance 
abuse, particularly use of cannabis in early adolescence, appears to be more prevalent in 
EOS (Kumra et al. 2005), may precipitate the earlier onset of psychosis (Schimmelmann et 
al. 2012;  Large et al. 2011), and lead to greater symptom severity and poor treatment 
response (Kumra et al. 2005).  The effect of these risk factors may be further exacerbated by 
urbanicity (Kuepper et al. 2011) and social adversity (Heinz et al. 2013). 
EOS is also associated with unfavourable clinical and psychosocial outcome (Röpcke 
and Eggers, 2005; Remschmidt et al, 2007; Schimmelmann et al, 2007; Vyas et al, 2007). A 
further concern is increased suicidality, particularly in adolescent patients  (Jarbin and Von 
Knorring, 2004; Falcone et al. 2010; Shoval et al. 2006; Sanchez-Gistau et al. 2013). Up to 
32% of AOS patients may attempt suicide prior to their first admission (Falcone et al. 2010; 
Shoval et al. 2006), up to 12% in the two years following the first admission (Sanchez-Gistau 
et al. 2013) and approximately 25% in the subsequent ten years (Jarbin and Von Knorring, 
2004). Moreover, the 10-year prevalence of completed suicide in EOS following the first 
admission is reported to be as high as 5% (Jarbin and Von Knorring, 2004).    
  Antipsychotic medication is the mainstay treatment for EOS as is the case of adult 
onset cases. However, antipsychotic agents, regardless of pharmacological class, are only 
partially effective in EOS with acute response rates ranging from 34-50% (Sikich et al. 2008; 
Findling et al. 2010). The prevalence of poor treatment responders in EOS is therefore 
consistently high (Sikich et al. 2008; Findling et al. 2010). As clozapine has shown superior 
efficacy in treatment-resistant adult patients with schizophrenia, several clinical trials and 
observational studies have examined its efficacy and tolerability in EOS (Schneider et al. 
2014). We have recently reviewed this literature (Schneider et al. 2014) which shows that 
clozapine is associated with significant symptomatic relief and sustained clinical 
improvement in EOS. These benefits need to be balanced against a wide-range of clozapine-
induced adverse drugs reactions (ADRs) that necessitate close monitoring of patients’ 
physical health. The most common ADRs in EOS are sedation and hypersalivation (reported 
in 90% of patients), followed by enuresis and constipation (up to 60%) ((Schneider et al. 
2014).). Weight gain and metabolic changes are also relatively common (8-22%) but 
emergent diabetes is infrequent (<6%) (Schneider et al. 2014). Although haematological 
ADRs are potentially the most concerning, neutropenia occurs in a small minority of EOS 
patients (6-15%) and is usually transient while agranulocytosis is rare (<0.1%) (Schneider et 
al. 2014). There are no reports of fatalities in this age group. The average all-cause 
discontinuation rate of clozapine in EOS is very low (< 6%) (Schneider et al. 2014).  
The most recent international guidelines recommend the use of clozapine  in 
refractory EOS and provide a clear framework for ADR monitoring (McClellan et al, 2013; 
NICE, 2013). Despite this, the use of clozapine in EOS is generally thought to be both limited 
and delayed. For example, less that 0.4% of all clozapine prescriptions in the UK are for EOS 
patients (Cirulli, 2005) and nearly 40% of psychiatrists working in child and adolescent 
inpatient units have never prescribed clozapine (Cirulli, 2005).  This suggests that clinical 
decision-making in connection to clozapine initiation in EOS is influenced by variables 
beyond clinical response or tolerability. However, systematic data addressing this issue are 
currently lacking. Accordingly, the purpose of this study was to identify the clinical features 
that predict clozapine treatment in EOS. We hypothesized that age at diagnosis, suicidality 
and cannabis abuse may emerge as significant predictors of clozapine treatment and that 
the influence of these factors may modified by sex,  urbanicity, and social adversity. 
  
 Experimental Procedures 
Case Identification  
 We used linked data from the Danish Psychiatric Central Research Register (DPCR) 
(Mors et al. 2011), the National Prescription Database (Kildemoes et al. 2011), the Danish 
Civil Registration System (CRS) (Pedersen et al. 2006) and the Integrated Database for 
Labour Market Research (IDA) (Munk-Jørgensen and Østergaard, 2011).  
The DCPR covers the entire Danish population including immigrants and contains 
information on all admissions to inpatient psychiatric facilities since 1969 and all visits to 
specialty outpatient and emergency services since 1995 (Mors et al. 2011, Munk-Jørgensen 
and Østergaard, 2011). Diagnoses both for patients and their first-degree relatives followed 
the International Classification of Diseases, 8th revision (ICD-8) (WHO, 1967) till 1994 and the 
10th revision (ICD-10) (WHO, 1992) thereafter. We used the DPCR to identify all patients 
with schizophrenia (ICD-8: 295.x9, excluding 295.75, and ICD-10: F20) diagnosed between 
December 31st 1994 and December 31st 2006. The same database was used to identify 
psychiatric diagnosis of the patients’ first-degree relatives. From the initial pool of 34,467 
patients we selected those with schizophrenia diagnosed prior to their 18th birthday. Age at 
diagnosis was based on the date of the first service contact during which a diagnosis of 
schizophrenia was recorded. Additional information extracted concerned number and 
duration of hospitalizations, cannabis abuse disorders, and suicide attempts (detailed 
definitions provided in the online data supplement).  
We used the national prescription database to extract data regarding antipsychotic 
use (Kildemoes et al. 2011). The database includes all prescription based medicines 
collected from pharmacies during outpatient status.  We collected data on all redeemed 
prescriptions for any antipsychotic medication till 31st December 2008. Dosage was 
calculated using defined daily doses (DDD) (WHOCC, 2009) corrected for bed-days as the 
national prescription database does not contain information about medications used during 
hospitalizations. 
The CRS contains continually-updated information on all Danish residents and was 
used to extract information about place of birth and residence. Information about patients’ 
parental death and psychiatric diagnoses in first degree family members were obtained by 
linking data from the CRS and the DPCR. The IDA was used to extract patients’ education 
and employment data.  
The study was approved by the Danish Data Protection Agency, National Board of 
Health and Statistics Denmark (currently renamed Danish Health and Medicine Authority). 
Approval from the National Scientific Ethical Committee was not required because register-
based data are anonymized. 
Predictors of Clozapine Initiation 
  The date of antipsychotic treatment initiation was defined as the redemption date 
of the first prescription for any antipsychotic agent. The variables examined as potential 
predictors of clozapine initiation were selected based on the previous literature for their 
association with earlier onset and/or increased illness severity in EOS.  We therefore 
considered sex, urbanicity at birth and the time of the diagnosis of schizophrenia, family 
adversity indexed by parental loss before patients’ 18th birthday, family history of 
schizophrenia among 1st degree relatives, duration of untreated illness, age at the time of 
the diagnosis of schizophrenia, and cannabis abuse and attempted suicide prior to or within 
the first year of diagnosis.  Detailed definitions are provided in the on line data supplement. 
 
Assessment of clinical and functional outcome 
 As the national registries do not hold data on symptom levels, we could only assess 
treatment response using surrogate measures. We based our choice on previous Danish 
registry data that show that the average time to all-cause discontinuation of clozapine is 
approximately 9 months (Uggerby et al, 2011). We therefore defined treatment response as 
having redeemed prescriptions for clozapine for a minimum of six consecutive months 
following initiation. Periods shorter than this may reflect discontinuation due to ADRs during 
titration while discontinuation after 6 months is likely to be influenced by non-specific 
factors affecting long-term adherence including refusal of on-going haematological 
monitoring. Functional outcome was based on the patients’ highest educational and 
employment level. Therefore information was collected only for those patients who were 20 
years or older by 31st December 2008. 
Statistical Analysis  
 We extracted data using SAS 9.2 (SAS Institute Inc, Cary, NC) and analysed using 
STATA 11 (Stata-Corp LP, College Station, Texas). We compared clozapine to non-clozapine 
treated patients and clozapine responders to non-responders on a range of demographic, 
clinical and outcome variables using appropriate parametric and non-parametric statistics.   
The association between each individual predictor variable and time to clozapine 
initiation was first examined using separate univariate cox proportional hazard models. 
Variables that predicted time to clozapine initiation at the level of p<0.10 were then entered 
in a multivariable cox model. Multicollinearity between predictors was measured using 
Variance Inflation Factor (VIF). VIF values >5 denote multicollinearity.  
  
Results 
We identified 662 cases with childhood or adolescent schizophrenia. We excluded 48 
patients who did not redeem any prescriptions for outpatient treatment. The final study 
population comprised 614 patients who were first diagnosed with schizophrenia at a mean 
age of 16.20 years. The socio-demographic, clinical treatment and functional characteristics 
of the sample are summarized in Table 1 and in supplemental Table S1 in the online data 
supplement. Clozapine was prescribed at least once to 108 patients (17.6% of the sample). 
The mean interval between onset of antipsychotic treatment and clozapine initiation was 
3.2 (2.9) years. Prior to this, patients had had approximately 3 (range: 1-10) therapeutic 
trials with different antipsychotics, mostly (61.6%) second generation agents as shown in 
supplemental Table S2 in the online data supplement.  
Characteristics of EOS patients prescribed clozapine   
Compared to patients who never received clozapine, patients who had been 
prescribed clozapine at least once had higher rates of cannabis abuse, were more likely to 
have attempted suicide, were marginally older, less likely to have lived in the suburban/rural 
areas at the time of diagnosis with schizophrenia, and less likely to be employed at the age 
of 20 years (Table 1).  No other differences were statistically significant (Table 1).   
Prediction of Clozapine initiation 
The results of the cox proportional hazard models are summarized in Table 3. 
Urbanicity either at birth (p=0.66) or at diagnosis (p=0.13), parental loss (p=0.98) and history 
of cannabis use (p=0.16) were not significant predictors of time to clozapine initiation. In 
contrast, older age at diagnosis [HR=1.25, 95%CI (1.06-1.48), p=.003], having attempted 
suicide [HR=1.98, 95% CI (1.23-3.20), p=.001], female sex [HR=0.69, 95%CI (0.46-1.04), 
p=0.05] and family history of schizophrenia [HR=1.89, 95%CI (0.98-3.66), p=0.05] were 
significant predictors and were entered into the multivariable cox proportional hazard 
model. In this final model, older age at diagnosis [HR=1.24, 95% CI (1.05-1.48), p=0.01]), 
positive family history of schizophrenia [HR=2.19, 95%CI (1.13-3.04), p=0.02] and having 
attempted suicide [HR=1.85, 95%CI (1.13-3.04), p=0.02] remained significant (all VIF <1.06) 
while sex did not [HR=0.71, 95%CI (0.46-1.10), p=0.13]. Graph 1 illustrates the Kaplan-Meier 
curves for the three significant predictors.  
Characteristics of patients remaining on clozapine for more than 6 months  
Of the 108 clozapine treated patients, 96 (88.9%) redeemed clozapine prescriptions for at 
least six consecutive months and thus were considered responders. Those who discontinued 
clozapine earlier than 6 months had higher rates of attempted suicide; otherwise the two 
groups were statistically comparable (Table 3). Numerically there was a suggestion that 
clozapine responders may have shorter hospital stays and possibly better occupational 
outcomes at age 20 years. However, the sample may have been underpowered to detect 
differences between those who redeemed clozapine prescriptions for less as opposed to 
more than 6 months (Table 3). 
 
 
 
 
 
  
Discussion 
We found that approximately 1 in every 5 patients with EOS redeemed at least one 
clozapine prescription, on average within 3-4 years from illness onset. Clozapine initiation 
was associated with older age at diagnosis, a history of suicide attempts and positive family 
history of schizophrenia. Prior to commencing clozapine, patients had been prescribed on 
average 3 different antipsychotics, mostly second generation agents (Table S2, on line data 
supplement). The majority of clozapine treated patients (88.9%) can be considered as 
having a favourable response since they continued to redeem clozapine prescriptions for 
more than 6 months.    
Our findings regarding antipsychotic exposure prior to clozapine in EOS are 
comparable to those in patients with adult onset schizophrenia.  Nielsen and colleagues 
(2012) used the same registers to characterize patients with adult onset schizophrenia 
(mean age of onset 26.2 years) that were first prescribed clozapine between January 1st 
1997 and December 31, 2005. They also found that clozapine was initiated after an average 
of 3 antipsychotic trials. The mean interval between the diagnosis of schizophrenia and 
clozapine initiation was 1-2 years which is shorter than in the EOS sample. Similar findings 
were also reported by Harrison et al (2010) based on data from adult patients commenced 
on clozapine between 1993 and 2007 in a large mental health clinic in Auckland, New 
Zealand (34). In the UK, the most recent study was conducted at the Maudsley Hospital in 
South London for patients commencing clozapine between 2006 and 2010 (Howes et al. 
2014). The authors reported that clozapine initiation occurred after an average of 5 
antipsychotic trials and suggested that this led to a delay in clozapine treatment of about 4 
years (Howes et al. 2014). Our data therefore suggest that, within Denmark at least, time to 
clozapine initiation in EOS, follows similar patterns to those seen in adult onset cases and is 
generally aligned with treatment recommendations to start clozapine after two 
unsuccessful therapeutic trials with different antipsychotics (McClellan et al. 2013; NICE, 
2013).  
 Key predictors of clozapine treatment In adult onset schizophrenia include increased 
use of services, particularly inpatient facilities, increased number and dose of antipsychotic 
medications, younger age of onset and male sex (Harrisson et al. 2010; Howes er al. 2011; 
Nielsen et al. 2012). In contrast, number of hospitalizations, level of antipsychotic use and 
sex did not differentiate between clozapine and non-clozapine treated EOS patients. Neither 
did we find an excess of males in the clozapine treated EOS group although this is often 
reported in adult schizophrenia (Harrisson et al. 2010; Howes et al. 2011; Nielsen et al. 
2012).  Another important difference between adult and early onset schizophrenia with 
regards to clozapine treatment concerns the effect of suicidality. A history of suicide 
attempts emerged as a key predictor of clozapine treatment in EOS. Evidence from several 
lines of research suggests that clozapine may reduce suicidality and suicide related mortality 
in schizophrenia (reviewed by Meltzer, 2012) and this may have influenced clinical decision-
making in this study. Our finding contrasts with a US study (Stroup et al. 2014) who found 
no association between suicide attempts/self-harm on clozapine initiation. Their sample 
consisted of 15,524 clozapine-treated patients with schizophrenia aged 18-64 years derived 
from national (45-state) Medicaid Analytic Extracts covering the years 2001-2005. It is not 
clear whether this reflects differences in clinical practice or in patients’ access to care 
following suicidal attempts or in reporting procedures.  
 Also contrary to the adult literature, clozapine treatment in EOS was associated with 
older age at diagnosis. This is not due to age-related restrictions in the use of clozapine 
specific to Denmark. It is possible that clinicians offer clozapine to older adolescents as they 
may consider them better able to understand the monitoring requirements and have better 
tolerability than younger adolescents or children. The association between clozapine 
initiation and positive family history of schizophrenia has not been examined in previous 
studies.  The presentation of schizophrenia in children and adolescents is uncommon and 
making the diagnosis can be challenging (Gochman et al, 2011). In this context, the presence 
of family history for the disorder may reassure clinicians about the validity of their diagnosis 
and may empower them to consider clozapine earlier.  
Methodological Considerations 
The strengths and limitation of this study reflect its register-based design. Detailed 
clinical information is not available in the registers. Consequently it was not possible to 
comment on symptomatic response to clozapine or to ascertain whether all eligible patients 
had been prescribed clozapine. Prescription data were available only for outpatient 
treatment.  It was not possible to ascertain whether some patients were offered clozapine 
during their hospital stay but refused or discontinued treatment very early due to ADRs or 
poor adherence with haematological monitoring. The major strength of the study is the 
availability of information from the complete Danish population which minimizes sampling 
and recall biases.  
Clinical Implications  
Our findings suggest that clinicians involved in the care of EOS patients are mindful of 
current guidelines for the use of clozapine in this age group and endeavour to align their 
practice accordingly. This is the first study to examine clozapine use in EOS using nationwide 
data. Our findings support the timely use of clozapine in EOS. The majority of EOS patients 
prescribed clozapine appeared to derive some benefit as they remained on this medication 
for longer than 6 months. We were not able to establish the degree of clinical improvement 
but continued use of clozapine may lead to reduced hospitalizations and improved 
vocational outcome. It was not possible to ascertain to what degree all potentially eligible 
patients were offered clozapine. It would be important to address this issue in further 
studies in order to identify potential barriers to clozapine use in this age group.  
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Table 1. Study Population 
 
 
Non-Clozapine 
Treatment Group 
(N=506) 
Clozapine 
Treatment Group 
(N=108) 
P 
Sociodemographic variables 
Sex  (n % male) 258 (50.99) (48) 44.44 0.22 
Urbanicity at diagnosis, n (%) 
Living in the capital 
Living in suburb of capital 
Living in provincial city  
Living in provincial town 
Living in rural area 
 
86 (17.03) 
113 (22.38) 
34 (6.73) 
128 (25.25) 
144 (28.51) 
 
20 (18.87) 
14 (13.21) 
9 (8.49) 
39 (36.79) 
24 (22.64) 
0.05 
Urbanicity at birth, n (%) 
Living in the capital 
Living in suburb of capital 
Living in provincial city  
Living in provincial town  
Living in rural area 
 
93 (21.08) 
88 (19.95) 
37 (8.39) 
109 (24.72) 
114 (25.85) 
 
20 (21.28) 
19 (20.21) 
8 (8.51) 
27 (28.72) 
20 (21.28) 
0.89 
Parental loss, n (%) 39 (7.71) 7 (6.48) 0.66 
Positive family history for schizophrenia, n (%)  31 (6.42) 12 (11.88) 0.06 
Clinical variables 
Age at schizophrenia diagnosis (years) 16.10 (1.64) 16.63 (1.03) .001 
History of attempted suicide, n (%) 70 (13.83) 24 (22.22) .03 
Cannabis abuse, n (%) 23 (4.55%) 11 (10.19) .02 
Treatment variables 
Duration of untreated illness (days) 335.33  (566.86) 417.92 (668.54) 0.31 
Number of hospitalisations (per year) 1.04 (1.71) 1.17 (1.17) 0.47 
Duration of hospitalisations (days per year) 80.01 (192.78) 103.91 (200.25) 0.27 
Defined Daily Dose of Antipsychotics (per year)* 2.31 (38.74) 3.91 (57.40) 0.74 
Number of antipsychotics prescribed prior to clozapine  --- 3.37 (2.26) --- 
Interval between first antipsychotic prescription and 
clozapine initiation (years) 
--- 3.2 (2.9) --- 
Clozapine initiation prior to age 18 years, n (%) --- 33 (30.56) --- 
Clozapine treatment for > 6 months, n (%) --- 96 (88.88) --- 
Functional Outcome variables 
Highest Educational Status, n (%)** 
Primary School 
High-School 
Vocational Education 
Higher Education, short-track 
Higher Education, medium and long-track 
 
423 (92.20) 
19 (4.36) 
12 (2.75) 
2 (0.46) 
1 (0.23) 
 
101 (97.87) 
0 (0.00) 
2 (2.13) 
0 (0.00) 
0 (0.00) 
0.28 
Highest Working Status, n (%)** 
Inside workforce 
Outside workforce 
Unemployed 
 
101 (22.10) 
354 (77.46) 
2 (0.44) 
 
11 (10.68) 
92 (89.32) 
0 (0.00) 
0.03 
Continuous variables are shown as mean (standard deviation) and categorical variables as number ( %) within group; * Defined daily Dose 
was corrected for bed-days per year; **Based on a sample of 457 non-clozapine and 103 clozapine treated patients who were at least 20 
years old in 2008; significant uncorrected p value in bold typeface 
 
 
 
 
 
Table 2. Univariate and adjusted hazard ratios from cox proportional hazard models 
predicting time to clozapine initiation 
 
 
 Univariate Models Multivariate Model 
 HR (95% CI) p HR (95% CI) P 
Sex 0.69 (0.46- 1.04) 0.05 0.71 (0.46-1.10) 0.13 
Age at diagnosis of schizophrenia  1.25 (1.06-1.48) .003 1.24 (1.05-1.48) 0.01 
Family history of schizophrenia 1.89 (0.98-3.66) 0.05 2.19 (1.13- 3.04) 0.02 
Urbanicity at birth  .98 (0.85-1.13) 0.81 --- --- 
Urbanicity at diagnosis 1.04 (0.90-1.20) 0.57 --- --- 
Parental loss  1.00 (0.46-2.17) 0.99 --- --- 
Premorbid cannabis use  1.60 (0.80-3.18) 0.21 --- --- 
Suicide attempts  1.98 (1.23-3.20) 0.001 1.85 (1.13-3.04) 0.02 
 
 
 
 
 
  
 Table 3. Comparison of patient that remained on clozapine for more than 6 months versus 
those who discontinued earlier 
 
 Discontinuation 
group  
(N=12) 
Continued 
treatment group 
(N=96) 
p 
Demographic variables  
Sex (male, n %) 5 (41.66) 43 (44.79) 0.83 
Clinical Variables 
Age at Diagnosis 16.71 (0.98) 16.62 (1.04) 0.76 
History of attempted suicide 5 (41.65) 19 (19.79) 0.03 
Cannabis use  1 (8.33) 10 (10.41) 0.41 
Treatment Variables 
 
   
Total Number Hospitalizations  18.67 (11.28) 20.58 (18.72) 0.73 
Duration of Hospitalizations (days) 604.5 (939.81) 442.06 (378.36) 0.24 
Functional  Outcome Variables  
 
Education (high school or higher, n %) 0 (0) 2.44% 0.61 
Working Status (within workforce, n %) 2 (16.67) 9 (9.37) 0.47 
Continuous variables are shown as mean (standard deviation) and categorical variables as number (%) within group 
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